The Fourth Department of Healthcare, China-Japan Friendship Hospital, Beijing, China.
College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Ann Palliat Med. 2021 May;10(5):5244-5251. doi: 10.21037/apm-20-1629. Epub 2021 May 14.
Alzheimer's disease (AD) has gradually increased as society has aged and is now a serious social problem. In the clinical treatment of AD, patients show improvement in cognitive function after treatment with the traditional Chinese medicine compound, Yizhi Sheng Hui (YZSH) decoction. This study systematically investigates the effect and pharmacology of the YZSH decoction on AD.
In this study, 24 SAMP8 AD model mice were randomly divided into three groups: an untreated control group, a group treated with the YZSH decoction, and a positive control group treated with donepezil hydrochloride. Eight SAMR1 mice were placed in the normal control group. A Morris water maze test and a step-down test were conducted at 8 and 13 weeks after continuous intragastric administration of the two drugs. After 13 weeks of administration, the hippocampal expression of Aβ1-42 and tau protein were measured.
There was no change in the latent period duration and the number of platform crossings in each group after 8 weeks of administration, but after 13 weeks of administration, the latent period of the treatment group and the positive control group were significantly shorter than the untreated control group. Initially, the SAMP8 mice showed a lower spatial exploration ability than the SAMR1 mice. However, after 13 weeks of administration, the treatment group and the control group exhibited a better exploration ability. Compared with the SAMR1 mice, the on-stage evasion time and step-down errors significantly increased in the untreated group. Compared with the untreated group, mice in the treatment group and the positive control group showed a shorter latent period after 8 weeks of administration, and the on-stage evasion time for both groups was significantly reduced after 13 weeks of administration. The treatment group showed fewer instances of electric shock. Hippocampal expression of Aβ1-42 was high in the untreated group, was much lower in the positive control group, and no Aβ1-42 expression was observed in the treatment group.
The YZSH decoction improved the learning and memory of mice with AD, related to the inhibition of Aβ1-42 expression.
随着社会老龄化,阿尔茨海默病(AD)逐渐增多,现已成为严重的社会问题。在 AD 的临床治疗中,中药复方益智升慧(YZSH)汤治疗后患者认知功能改善。本研究系统探讨 YZSH 汤对 AD 的作用及药理学。
本研究将 24 只 SAMP8 AD 模型小鼠随机分为 3 组:未治疗对照组、YZSH 汤组和阳性对照多奈哌齐组。8 只 SAMR1 小鼠置于正常对照组。连续灌胃给药 8、13 周后,行 Morris 水迷宫试验和跳台试验。给药 13 周后,检测海马 Aβ1-42 和 tau 蛋白表达。
给药 8 周后,各组潜伏期和平台穿越次数无变化,给药 13 周后,治疗组和阳性对照组潜伏期明显短于未治疗对照组。SAMP8 小鼠初始空间探索能力较 SAMR1 小鼠差,给药 13 周后,治疗组和对照组探索能力增强。与 SAMR1 小鼠相比,未治疗组上平台逃避时间和跳台错误显著增加。与未治疗组相比,给药 8 周后治疗组和阳性对照组潜伏期缩短,两组上平台逃避时间均明显减少。治疗组电击次数减少。未治疗组海马 Aβ1-42 表达高,阳性对照组明显降低,治疗组未见 Aβ1-42 表达。
YZSH 汤改善 AD 模型小鼠学习记忆能力,与抑制 Aβ1-42 表达有关。